Panobinostat is a potent histone deacetylase inhibitor indicated for the treatment of multiple myeloma in patients who have received at least two prior therapies, including bortezomib and an immunomodulatory… Read more







Panobinostat is a potent histone deacetylase inhibitor indicated for the treatment of multiple myeloma in patients who have received at least two prior therapies, including bortezomib and an immunomodulatory agent. By targeting histone deacetylase enzymes, this pharmaceutical compound promotes cell cycle arrest and apoptosis in cancer cells. This category provides essential analytical tools for pharmaceutical research, including Panobinostat reference standards, related impurities, and stable isotope labelled compounds such as deuterated derivatives. These high-purity reference materials are critical for impurity profiling, method validation, and rigorous quality control testing of the active pharmaceutical ingredient. Laboratories rely on these labelled analogues and specific degradation products, including N-nitroso impurities, to ensure accurate identification and quantification during stability testing and regulatory analysis throughout the drug development lifecycle.